Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on April 1, 2025, and filed on April 2, 2025. The filing details a share repurchase executed through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, margin, or debt metrics are provided in this document.
- Shares Purchased (April 1, 2025): 630,000 ordinary shares.
- Price Range: Lowest 1,465.00 GBp; Highest 1,496.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,479.36 GBp.
- Total Buyback Since Feb 24, 2025: 18,866,887 ordinary shares.
- Treasury Shares Held: 187,937,190 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,127,284,542 ordinary shares.
- Total Voting Rights: 4,127,284,542.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares following the April 1 transaction. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties. Investors are directed to the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F for details on factors that may cause actual results to differ from projections.
Investor Verification Checklist
- Verify the total number of shares in issue (4,127,284,542) for calculating ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the status of the non-discretionary buyback agreement entered into on February 24, 2025, to understand remaining capacity.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for comprehensive risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the total volume of shares repurchased under the current programme.